Autoantibodies in early rheumatoid arthritis - Brasília cohort - results of a three-year serial analysis

Revista Brasileira de Reumatologia

Volumn 51, Issue 6, 2011, Pages 558-571

  da Mota, Licia Maria Henrique ^a,f   dos Santos Neto, Leopoldo Luiz ^b   Pereira, Ivânio Alves ^c   Burlingame, Rufus ^d   Ménard, Henri A ^e   Laurindo, Ieda Maria Magalhães ^c  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INOVA DIAGNOSTICS INC   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f Centro Médico de Brasília   (Brazil)

Author keywords

Citrulline; Rheumatoid arthritis; Rheumatoid factor; Vimentin

Indexed keywords

AUTOANTIBODY; CITRULLINATED VIMENTIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE 3 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE 3.1 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; DRUG DERIVATIVE; VIMENTIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BRAZIL; CLINICAL ARTICLE; COHORT ANALYSIS; DIAGNOSTIC VALUE; EARLY RHEUMATOID ARTHRITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; BLOOD; IMMUNOLOGY; MIDDLE AGED; TIME;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BRAZIL; CITRULLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; TIME FACTORS; VIMENTIN; YOUNG ADULT;

EID: 82955194479     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. van der Horst-Bruinsma IE, Speyer I, Visser H, Breedveld FC, Hazes JM. Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998; 37(10):1084-8.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum 1988; 31(3):315-24.
3. Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005; 7(3):R592-603.
4. Da Mota LM, Laurindo IM, Dos Santos Neto LL. Demographic and clinical characteristics of a cohort of patients with early rheumatoid arthritis. Rev Bras Reumatol 2010; 50(3):235-48.
5. Da Mota LM, Dos Santos Neto LL, Burlingame R, Ménard HA, Laurindo IM. Laboratory characteristics of a cohort of patients with early rheumatoid arthritis. Rev Bras Reumatol 2010; 50(4):375-88.
6. NellDuxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefer E et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2009; 19 Jan on line (abstract) [epub ahead of print].
7. Tedesco A, D'Agostino D, Soriente I, Amato P, Piccoli R, Sabatini P. A new strategy for the early diagnosis of rheumatoid arthritis: a combined approach. Autoimmun Rev 2009; 8(3):233-7.
8. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146(11):797-808.
9. Renaudineau Y, Jamin C, Saraux A, Youinou P. Rheumatoid factor on a daily basis. Autoimmunity 2005;38(1):11-6.
10. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 2003; 42(8):939-46.
11. Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996; 55(3):157-61.
12. Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63(9):1079-84.
13. Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1050:295-303.
14. Wolfe F, Cathey MA, Roberts FK. The latex test revised. Rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 1991; 34(8):951-60.
15. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43(1):155-63.
16. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005; 19(1):55-72.
17. Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary J Y, Thorel JB et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002; 47(2):155-65.
18. Procaccia S, Gasparini A, Colucci A, Lanzanova D, Bianchi M, Forcellini P et al. ELISA determined IgM, IgG and IgA rheumatoid factors in rheumatoid arthritis and in other connective tissue diseases. Clin Exp Rheumatol 1987; 5(4):335-42.
19. Westwood OM, Nelson PN, Hay FC. Rheumatoid factor: what ́s new? Rheumatology Oxford 2006; 45(4):379-85.
20. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value for anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65(7):845-51.
21. Dörner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16(3):246-53.
22. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2002; 2(3):236-43.
23. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chalès G, Le Henaff C et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 2003; 30(12):2535-9.
24. Sauerland U, Becker H, Seidel M, Schotte H, Willeke P, Schorat A et al. Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann N Y Acad Sci 2005; 1050:314-8.
25. Dubrous P, Gardet V, Hugard L. Value of anti-cyclic citrullinated peptides antibodies in comparison with rheumatoid factor for rheumatoid arthritis diagnosis. Pathol Biol (Paris) 2005; 53(2):63-7.
26. Silveira IG, Burlingame RW, von Mühlen CA, Bender AL, Staub HL. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 2007; 26(11):1883-9.
27. Vallbracht I, Helmke K. Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmun Rev 2005; 4(6):389-94.
28. Solanki K, Spellerberg M, Chapman P, Moller P, O'Donnell J. Anti-cyclic citrullinated antibodies: complementary to IgM rheumatoid factor in the early diagnosis of rheumatoid arthritis. N Z Med J 2004; 117(1203):U1097.
29. Araki C, Hayashi N, Moriyama M, Morinobu S, Mukai M, Koshiba M et al. Usefulness of anti-cyclic citrullinated peptide antibodies (anti-CCP) for the diagnosis of rheumatoid arthritis. Rinsho Byori 2004; 52(12):966-72.
30. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM et al. Effcacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56(5):1424-32.
31. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A et al. Anti-CCP antibodies measured at disease onset help identify soronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006; 45(4):478-80.
32. Anjos LME, Pereira IA, d'Orsi E, Seaman A, Burlingame RW, Morato EF. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 2009; 28(2):153-8.
33. Vieira LMEA, d'Orsi E, Pereira IA, Morato EF, Burlingame RW. Rheumatoid arthritis diagnosis: a comparative study of second and third generation anti-cyclic citrullinated peptide (CCP) antibody ELISAs. INOVA Newsletter 2007; 2:8-9.
34. Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008; 27(1):77-83.
35. Wu R, Shovman O, Zhang Y, Gilburd B, Zandman-Goddard G, Shoenfeld Y. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol 2007; 32(1):47-56.
36. Luis Caro-Oleas J, Fernández-Suárez A, Reneses Cesteros S, Porrino C, Núñes-Roldán A, Wichmann Schlipf I. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clin Chem Lab Med 2007; 45(10):1396-401.
37. Lutteri L, Malaise M, Chapelle JP. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 2007; 386(1-2):76-81.
38. Szekanecz Z, Burlingame R. The INOVA CCP 3.1 IgA/IgG ELISA represents significant improvement in the laboratory diagnosis of rheumatoid arthritis. INOVA Newsletter 2007; 2:6-7.
39. Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007; 53(8):1527-33.
40. Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 2009; 36(4):706-11.
41. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al. Antibodies against citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48(10):2741-9.
42. Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008; 35(10):1972-7.
43. Vossenaar ER, Després N, Lapointe E, van de Heijden A, Lora M, Senshu T et al. Rheumatoid arthritis specifc anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6(2):R142-50.
44. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008; 35(6):1002-8.
45. Ménard HA. Effects of RA treatments on citrullinated immune systems in vitro and in vivo. 28th European Workshop on Rheumatology Research, March 1, 2008, Toulouse, France.